Rabbit Recombinant Monoclonal GSK3 beta phospho S9 antibody. Suitable for IHC-P, Dot, WB, ICC/IF and reacts with Human, Synthetic peptide samples. Cited in 111 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IHC-P | IP | Flow Cyt | Dot | WB | ICC/IF | |
---|---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Expected | Tested | Tested |
Synthetic peptide | Not recommended | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10000 - 1/20000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Select an associated product type
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1 (PubMed:11430833, PubMed:12554650, PubMed:14690523, PubMed:16484495, PubMed:1846781, PubMed:20937854, PubMed:9072970). Requires primed phosphorylation of the majority of its substrates (PubMed:11430833, PubMed:16484495). In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis (PubMed:8397507). May also mediate the development of insulin resistance by regulating activation of transcription factors (PubMed:8397507). Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase (PubMed:8397507). In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes (PubMed:12554650). Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA (PubMed:1846781). Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin (PubMed:9072970). Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules (PubMed:14690523). MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease (PubMed:14690523). Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex (PubMed:20937854). Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair (By similarity). Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA) (By similarity). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes (By similarity). Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation (By similarity). Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin (PubMed:9819408). Is necessary for the establishment of neuronal polarity and axon outgrowth (PubMed:20067585). Phosphorylates MARK2, leading to inhibition of its activity (By similarity). Phosphorylates SIK1 at 'Thr-182', leading to sustainment of its activity (PubMed:18348280). Phosphorylates ZC3HAV1 which enhances its antiviral activity (PubMed:22514281). Phosphorylates SNAI1, leading to its ubiquitination and proteasomal degradation (PubMed:15448698, PubMed:15647282, PubMed:25827072, PubMed:29059170). Phosphorylates SFPQ at 'Thr-687' upon T-cell activation (PubMed:20932480). Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including BMAL1, CLOCK and PER2 (PubMed:19946213, PubMed:28903391). Phosphorylates FBXL2 at 'Thr-404' and primes it for ubiquitination by the SCF(FBXO3) complex and proteasomal degradation (By similarity). Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation (PubMed:19946213). Phosphorylates BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation (PubMed:28903391). Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509). Regulates the circadian rhythmicity of hippocampal long-term potentiation and BMAL1 and PER2 expression (By similarity). Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, activating KAT5/TIP60 acetyltransferase activity and promoting acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer (PubMed:30704899). Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation (PubMed:18846110). Phosphorylates E2F1, promoting the interaction between E2F1 and USP11, stabilizing E2F1 and promoting its activity (PubMed:17050006, PubMed:28992046). Phosphorylates mTORC2 complex component RICTOR at 'Thr-1695' which facilitates FBXW7-mediated ubiquitination and subsequent degradation of RICTOR (PubMed:25897075). Phosphorylates FXR1, promoting FXR1 ubiquitination by the SCF(FBXO4) complex and FXR1 degradation by the proteasome (By similarity). Phosphorylates interleukin-22 receptor subunit IL22RA1, preventing its proteasomal degradation (By similarity).
Glycogen synthase kinase-3 beta, GSK-3 beta, Serine/threonine-protein kinase GSK3B, GSK3B
Rabbit Recombinant Monoclonal GSK3 beta phospho S9 antibody. Suitable for IHC-P, Dot, WB, ICC/IF and reacts with Human, Synthetic peptide samples. Cited in 111 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Glycogen synthase kinase 3 beta or GSK3 beta is a serine/threonine protein kinase that regulates various cellular processes. It is also referred to as GSK3B and has a molecular weight of approximately 47 kilodaltons (kDa). This enzyme is widely expressed in many tissues with notably high expression levels in the brain. Mechanically GSK3 beta phosphorylates target proteins affecting their activity stability and interactions with other proteins.
As an important regulatory protein GSK3 beta plays a role in multiple cellular functions including metabolism cell cycle and cell signaling. It often interacts with components in signaling complexes and modulates the activity of these complexes involving phosphorylation. It is involved in the regulation of transcription factors such as c-Myc and β-catenin influencing cell fate and survival. This ability to modulate diverse functions highlights GSK3 beta's importance in cellular regulation.
GSK3 beta participates in significant signaling pathways such as the Wnt/β-catenin and insulin signaling pathways. In the Wnt pathway GSK3 beta phosphorylates β-catenin marking it for degradation which regulates gene transcription. In insulin signaling it interacts with proteins like AKT to mediate glycogen synthesis. These interactions highlight its role in maintaining cellular homeostasis and energy balance.
GSK3 beta has implications in Alzheimer's disease and type 2 diabetes. It is associated with tau protein hyperphosphorylation and neurofibrillary tangles in Alzheimer's disease. In diabetes its role in insulin signaling impacts glucose metabolism. Further GSK3 beta's dysfunction relates to disrupted signaling related to these conditions positioning it as a potential therapeutic target.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Cell line: HeLa (human cervix adenocarcinoma)
Target: ab75814 anti-GSK3 beta (phospho S9)
Secondary: Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit
Fixative: 4% PFA
Permeabilization: 0.1% Triton-X
Nuclear counter stain: DAPI
Confocal image showed increased cytoplasmic staining after Calyculin A (CA) (Calyculin A, protein phosphatase inhibitor ab141784 100ng/ml, 10min) treatment on Hela cells. The LP treatment decreased the increased cytoplasmic staining caused by CA.
Anti-GSK3 beta antibody [Y174] ab32391 was used as a control for ab75814. The results showed cytoplasmic staining on untreated, CA and CA+LP treated Hela cells.
Blocking buffer: 5% NFDM/TBST for the first 3 lanes, 2% BSA/TBST for the second 3 lanes.
Dilution buffer: 5% NFDM/TBST for the first 3 lanes, 2% BSA/TBST for the second 3 lanes.
All lanes: Western blot - Anti-GSK3 beta (phospho S9) antibody [EPR2286Y] (ab75814) at 1/20000 dilution
Lane 1: Untreated HeLa cell lysate at 10 µg
Lane 2: HeLa cells were starved for 3 hours then treated with Calyculin A (100nM) for 30 minutes. at 10 µg
Lane 3: HeLa cells were starved for 3 hours then treated with Calyculin A (100nM) for 30 minutes. The membrane was treated with alkaline phosphatase. at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 46 kDa
Observed band size: 47 kDa
Exposure time: 5s
Immunohistochemical analysis of paraffin-embedded human breast cancer tissue labelled with untreated ab75814 (top-left) at a dilution of 1/1000, alkaline phosphatase treated ab75814 (top-right) at a dilution of 1/1000, untreated Anti-GSK3 beta antibody [Y174] ab32391 (bottom-left) at a dilution of 1/1000 and alkaline phophatase treated Anti-GSK3 beta antibody [Y174] ab32391 (bottom-right) at a dilution of 1/1000. Goat Anti-Rabbit IgG H&L (HRP) ab97051 was used as secondary antibody at a dilution of 1/500 and counterstained with hematoxylin.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Dot blot analysis of GSK3 beta (pS9) peptide (Lane 1) and GSK3 beta non-phospho peptide (Lane 2) labelling GSK3 (pS9) with purified ab75814 at a dilution of 1/1000. Goat Anti-Rabbit IgG H&L (HRP) ab97051 (Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/100000.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Western blot - Anti-GSK3 beta (phospho S9) antibody [EPR2286Y] (ab75814) at 1/20000 dilution
Lane 1: 293T cell lysates, untreated at 10 µg
Lane 2: 293T cell lysates, treated with Calyculin A at 10 µg
All lanes: goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 46 kDa
Observed band size: 47 kDa
Immunohistochemical analysis of paraffin-embedded human breast tissue labelled with untreated ab75814 (phospho) (top-left) at a dilution of 1/1000, alkaline phosphatase treated ab75814 (phospho) (top-right) at a dilution of 1/1000, untreated Anti-GSK3 beta antibody [Y174] ab32391 (bottom-left) at a dilution of 1/1000 and alkaline phophatase treated Anti-GSK3 beta antibody [Y174] ab32391 (bottom-right) at a dilution of 1/1000. Goat Anti-Rabbit IgG H&L (HRP) ab97051 was used as secondary antibody at a dilution of 1/500 and counterstained with hematoxylin.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com